Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The European Society for Medical Oncology (ESMO) Congress is one of the foremost global meetings in oncology, bringing together clinicians, researchers, patient advocates, and industry leaders to advance cancer care. VJOncology covered the ESMO 2025 Congress in Berlin, Germany, which featured in-depth presentations on pivotal clinical trials, emerging therapies, and expert discussions shaping the future of medical oncology. Stay tuned for exclusive interviews and coverage of the most anticipated updates from ESMO 2025.
View all videos

ESMO 2025

17–21 October 2025 | Berlin, Germany

ESMO 2025

17–21 October 2025 | Berlin, Germany
The European Society for Medical Oncology (ESMO) Congress is one of the foremost global meetings in oncology, bringing together clinicians, researchers, patient advocates, and industry leaders to advance cancer care. VJOncology covered the ESMO 2025 Congress in Berlin, Germany, which featured in-depth presentations on pivotal clinical trials, emerging therapies, and expert discussions shaping the future of medical oncology. Stay tuned for exclusive interviews and coverage of the most anticipated updates from ESMO 2025.
View all videos

Watch this year's highlights!

View all videos
1:41
SERDs in premenopausal breast cancer: improving outcomes & treatment options
Antonio Llombart-Cussac • 20 Oct 2025
0:49
AI-generated synthetic real-world data to evaluate cancer treatment outcomes
Eddy Saad • 19 Oct 2025
0:44
Evaluating toxicity from enzalutamide in the ENZARAD trial
Paul Nguyen • 19 Oct 2025
0:37
AI-generated synthetic real-world data to accelerate oncology research
Eddy Saad • 19 Oct 2025

Skin Cancer

View all
2:09
First line IO102-IO103 vaccine plus pembrolizumab in advanced melanoma
Ines Pires Da Silva • 19 Oct 2025
2:44
Phase Ia/b trial of IMA203, a PRAME-directed TCR therapy, in uveal melanoma
Sapna Patel • 17 Oct 2025

Breast Cancer

View all
3:29
DESTINY-Breast05: T-DXd vs T-DM1 in high-risk HER2+ early breast cancer
Charles Geyer • 19 Oct 2025
1:23
MonarchE: Ki-67 dynamics and prognostic value in HR+/HER2- breast cancer
Shigehira Saji • 19 Oct 2025

Gastrointestinal cancer

View all
2:06
IMbrave152/SKYSCRAPER-14: tiragolumab, atezolizumab & bevacizumab in HCC
Stephen Lam Chan • 20 Oct 2025
8:14
STELLAR-303 primary OS analysis: zanzalintinib + atezolizumab vs regorafenib in pretreated mCRC
Anwaar Saeed • 18 Oct 2025

Genitourinary cancer

View all
0:50
Neoadjuvant nivolumab with or without visugromab in cisplatin-ineligible MIBC
Clara Steiner • 18 Oct 2025
2:36
SunRISe-4: primary and biomarker results of TAR-200 & cetrelimab in MIBC
Andrea Necchi • 18 Oct 2025

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals